Posted in | News | Nanomedicine

Epeius Biotechnologies Files Patent for Leading Tumor-Targeted Gene Delivery Systems

Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic (or disease-seeking) targeting.

These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the USA for targeted gene delivery in vivo. Together these clinical patents provide additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent Rexin-G(R) -- the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.

Based on recent breakthroughs in tumor-targeting and nanotechnology, a new generation of powerful biological anti-cancer agents that are exceedingly precise and highly selective for diseased tissues is currently in clinical development. Anti-cancer agents such as Rexin-G(R) can be delivered by simple intravenous infusion, yet are programmed to seek-out and accumulate selectively in primary and metastatic lesions that have spread throughout the body, delivering a tumor-killing gene while sparing normal cells and tissues. Representing the world's first targeted genetic medicine proven to be both safe and effective in the clinic, Rexin-G(R) is commercially available in the Philippines -- for use in all solid tumors that are refractory to standard chemotherapy -- and is currently in clinical trials in the USA for several types of cancer.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.